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Large bone defects naturally regenerate via a highly vascularized
tissue which progressively remodels into cartilage and bone.
Current approaches in bone tissue engineering are restricted by
delayed vascularization and fail to recapitulate this stepwise differ-
entiation toward bone tissue. Here, we use the morphogen Sonic
Hedgehog (Shh) to induce the in vitro organization of an endo-
thelial capillary network in an artificial tissue. We show that endo-
genous Hedgehog activity regulates angiogenic genes and the
formation of vascular lumens. Exogenous Shh further induces the
in vitro development of the vasculature (vascular lumen formation,
size, distribution). Upon implantation, the in vitro development
of the vasculature improves the in vivo perfusion of the artificial
tissue and is necessary to contribute to, and enhance, the forma-
tion of de novo mature bone tissue. Similar to the regenerating
callus, the artificial tissue undergoes intramembranous and endo-
chondral ossification and forms a trabecular-like bone organ includ-
ing bone-marrow-like cavities. These findings open the door for
new strategies to treat large bone defects by closely mimicking
natural endochondral bone repair.
angiogenesis ∣ endochondral ossification ∣ regenerative medicine ∣
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Large bone defects with interfragmentary spaces and mobilityregenerate via a highly vascularized callus which stabilizes
the fracture site and progressively remodels into a bone organ (1).
This callus is composed of a shell formed by intramembranous
ossification (IO) and a core of highly vascularized fibrocartilage
which undergoes endochondral ossification (EO) (1). The vascu-
larization of the callus is quantitatively important and persists
until the normal medullar, periosteal, and osseous blood supply
is reestablished (2).
Current bone tissue engineering therapies often use bone-mar-
row–derived mesenchymal stem cells as an easily collectable and
abundant source of cells with high expansion and chondrogenic/
osteogenic differentiation capacity (3–4). However, these implants
currently have limited survival and functionality due to a lack of
vascularization (5). To overcome this problem, we previously de-
monstrated that endothelial cells can form a vascular network in
vitro which can rapidly anastamose with the host vasculature upon
implantation (6). Our data and others (7–9) suggest that such an
engineered vasculature must rapidly develop and become perfused
upon implantation to prevent the regression of capillaries (8), form
functional blood vessels (6), and possibly contribute to the forma-
tion of new tissues. These results raised two important questions in
vascular tissue engineering. First, does the in vitro development of
the vasculature improve its in vivo functionality? Second, if this
vasculature becomes functional in vivo, can it contribute to and
enhance tissue formation?
Hedgehog (Hh) proteins act as archetypical morphogens
regulating multiple processes during embryonic development.
Hh signaling is relatively silent during homeostasis but reactivates
during several adult regenerative processes, participates in neo-
vascularization (10, 11–14), and in fracture healing (10–15).
Among the three human Hh genes (Sonic, Indian, and Desert
Hedgehog), Sonic Hedgehog (Shh) is the most expressed, is
essential for endothelial tube formation during vascular embryo-
nic development (16), neovascularization upon adult trauma, and
wound healing (12–14, 17–18).
Here, we reasoned that Shh can be used to promote the in vitro
development of engineered blood vessels to improve endochon-
dral bone repair. Our data demonstrate that Shh promotes the
in vitro development of engineered blood vessels which resulted,
in vivo, in an improved perfusion of the implants and an
enhanced formation of mature bone via a combination of intra-
membranous and endochondral ossification.
Results
Endogenous Hedgehog Signaling Regulates Lumen Formation in an
Engineered Vasculature. The coculture of cellular aggregates of
hMSC (92%) and huvEC (8%) supports the formation of a
primitive three dimensional vascular network mainly composed
of cord-like structures and including some lumens [optimized
by us earlier (19–20)] (Fig. 1A). We previously demonstrated that
these vascular structures do not become rapidly functional upon
implantation possibly due to a lack of maturation (19–20). Con-
sistent with a role of Hh during vascular tube formation (16), we
found that an inhibition of the canonical Hh signaling pathway
using cyclopamine (5 μM), a Smo modulator (21) (day 0 to 12),
impaired the formation of lumens (2-fold, p ¼ 0.002, Fig. 1 B
and C). A partial inhibition from day 4 to 12 was sufficient
(p ¼ 0.001), which suggests a later role for Hh in the develop-
ment of lumens (Fig. 1C). A genetic screen (day 12) revealed that
cyclopamine stimulation significantly regulated 303 genes among
which 58 are directly linked to hedgehog signaling or angiogenesis
(Figs. 1 D and E, Fig. S1). Cyclopamine treatment regulated
two Hh inhibitors (GAS1 and RAB23, Fig. 1D) and the two Hh
target signaling pathwaysWnt and TGF (Fig. S1). Consistent with
current knowledge on vascular lumen formation (22), expression
of laminins (alpha 1, 3, 4, 5, beta 2) and integrins (alpha 2, 7, beta
5) were regulated (Fig. 1E) along with axon guidance molecules
(ephrin alpha 1, beta 1, 2, semaphorins 3G, 5A, 6A, 6D) and
cytoskeletal elements (Fig. S1). These results demonstrate a role
for endogenous Hh activity in regulating the formation of vascu-
lar structures and lumens.
Exogenous Sonic Hedgehog Protein Induces Vascular Lumen Forma-
tion in Vitro.We tested the potential for exogenous Shh to improve
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the formation of vascular lumens in vitro. A dose response assay
in the physiological range (0.5–30 nM) (23) revealed a classical
morphogen response inducing dose-dependent effects (Fig. 2A).
0.5 nM Shh induced a decrease in the number of lumens
(3.25 lumens∕mm2, 13 lumens∕mm2 in the control, p < 0.05)
while concentrations above 10 nM induced an increase in lumen
formation up to 3.4 fold (44 lumens∕mm2, p < 0.01) (Fig. 2A).
This resulted in a lumenization (opening) of the vascular struc-
tures covering up to 5.5% of the tissue area (7.5 fold increase at
10 nM ; 0.73% at 0 nM and 0.13% at 0.5 nM, Fig. 2B). This effect
was inhibited by cyclopamine (10 nM Shh, p < 0.05, Fig. 2C). A
later stimulation (day 9 to 12) was sufficient, which correlated
with the previous observation suggesting a later role for Shh in
the development of lumens (Fig. 2D). The total vessel length area
(total CD31+ area, mm2∕mm2) was unchanged (Fig. S2A) and
the proliferation of huvEC in serum-free medium on 2D plastic
decreased upon Shh stimulation (Fig. S2B). These results suggest
that the increase in vascular lumens formation is not due to an
increase in endothelial cell number. We concluded that Shh in-
duced the formation of lumens independently of endothelial cell
proliferation. Purmorphamine, a pharmacological activator of
Hh pathway which shunts the Ptc receptor and directly unleashes
Smo inhibition (24) induced a similar effect (day 8 to 12, Fig. 2E).
We compared the effect induced by Shh to classical anti- and
proangiogenic factors TGFB1, VEGF, and Ang1 (Fig. 2F). TGFB1
(10 ng∕mL), an inhibitor of endothelial cell proliferation and mo-
tility (25), dramatically decreased lumen formation (TGFB1:
0.8 lumen∕mm2, control: 10.5 lumens∕mm2, p < 0.05). VEGF
and Ang1 did not affect lumen formation. These findings correlate
with previous observations that vascular networks formed in multi-
cellular aggregates are not responsive to VEGF (26). The lumen
formation induced by Shh was reproduced using a commercially
available hMSC population (Lonza Group Ltd.) (Fig. S3). These
results suggest that exogenous Shh acts as a typical morphogen
modulating vascular lumen formation based on its concentration.
Sonic Hedgehog Modulates the Distribution Profile of Vascular
Lumens. To test the effect of exogenous Shh at the tissue level, we
observed the distribution profiles of vascular lumen areas and
their relative diameters (Fig. 2 G and H). The untreated group
(control group) and the group treated with 0.5 nM Shh developed
uniformly small lumens with an average diameter of 26 μm
(Table S1) and an exponential distribution reflecting the preva-
lence of capillaries (Control group: Median lumen diameter ¼
21 μm, 90th percentile ¼ 35 μm, Fig. 2 G and H). In the group
treated with 10 nM Shh, the distribution was normal, wider
with an average lumen diameter of 47 μm, significantly higher
than in the control group (p < 0.0003, Table S1) and included
lumens of middle and large diameters (10 nM Shh group:
Median lumen diameter ¼ 35 μm, 90th percentile ¼ 69 μm). In
contrast, the group treated with high Shh concentration (30 nM)
had an average lumen diameter of 34 μm, similar to the control
(p > 0.05) with predominant small diameter lumens (30 nM Shh
group: Median lumen diameter ¼ 24 μm, 90th percentile ¼
49 μm, Table S1). These results suggest that, at a tissue level, exo-
genous Shh modulates the size and distribution profile of lumens.
A concentration of 10 nM induced a maximal lumenization of the
vascular structures (5.5% of the tissue area, Fig. 2 A and B) and a
normal, spread distribution of the lumen sizes reminiscent of a
normal vascular hierarchy (Fig. 2 G and H). These results are
consistent with in vivo observations of Shh-induced neovascu-
larization in ischemic hindlimb (11) and with the notion of
morphogen.
Regulation of the Expression of Extracellular Matrix-Related Genes.
We tested the possibility that, besides vascular development, Shh
might regulate the production of a bone- and cartilage-related
extracellular matrix (ECM). Using quantitative reverse transcrip-
tase (qRT)-PCR to analyze mRNA levels, we observed that the
stimulation of the coculture with Shh (10 nM, day 4 to 12) upre-
gulated the expression of collagen type X (21 fold, p ¼ 0.04,
Fig. 3A), an effect inhibited by cyclopamine treatment (5 μM,
day 4 to 12). Other bone and cartilage ECM marker genes re-
mained similar (Collagen I, collagen II, aggrecan) (Fig. 3C).
We used histology and immunostaining to assess protein expres-
sion. Masson-Goldner staining revealed the presence of similar
levels of collagen type I upon Shh treatment (green stain,
Fig. S4). Neither the presence of collagen type II nor collagen
type X was detectable by imunohistochemistry. We concluded
that the mature proteins of collagen type II and X are either ab-
sent or present at very low levels in this coculture (Fig. 3B, Top)
and not significantly modulated by Shh. The stimulation of the
coculture with TGFB1 (10 ng∕mL), an inducer of chondrogenic
differentiation in hMSC, led to the production of collagen type II
but to the concomitant disappearance of the CD31+ network
(Fig. 3B, Bottom).
The Engineered Vasculature Increases Implant Perfusion in Vivo. To
evaluate the potential in vivo functionality of the vasculature,
implants composed of cellular aggregates and osteoinductive
ceramic granules (27) in a collagen type I matrix were implanted
subcutaneously in immuno-compromised mice. Cellular aggre-
gates were formed with either hMSC alone (group 1) ; hMSC
treated with 10 nM Shh (day 4 to 12, group 2) ; hMSC and huvEC
(group 3); hMSC and huvEC treated with 10 nM Shh (day 4 to 12,
group 4). Implants were first explanted and analyzed after
5 weeks. The engineered vasculature anastamosed with the host
vasculature as demonstrated by the presence of erythrocytes in
human CD31+ lumens (Fig. 4A). Implant perfusion was con-
Fig. 1. Endogenous Hh activity regulates angiogenic genes and the forma-
tion of lumens. Multicellular aggregates of hMSC (92%) and huvEC (8%)
aggregated in vitro and formed a primitive 3D vascular network including
few lumens (day 12, lumens are indicated by arrow heads) (A). A specific
pharmacological inhibition of the Hh pathway from day 0 and from day 4
using cyclopamine (5 μM) decreased the number of lumen formed [(B) from
day 0 to 12, (C), n ¼ 4 sections × 4 samples]. Genome-wide genetic screen
on cyclopamine treated-multicellular aggregates revealed the regulation of
two main inhibitors of the canonical Hh pathway (GAS1, RAB23) (D) and the
regulation of angiogenic molecules (E). Laminins and integrins are of espe-
cially relevant to the formation of vascular lumens (E). All presented genes
are significantly regulated as compared to vehicle-treated multicellular ag-
gregates. VEGF: vascular endothelial growth factor; ANGPTL: angiopoie-
tin-like; LAMA: laminin alpha; LAMB: laminin beta; ITGA: integrin alpha;
ITGB: integrin beta; VCAM: vascular cell adhesion molecule; NOS: nitric oxide
synthase. Errors bars are S.D. Scale bars are 100 μm. ** signifies a p-value
<0.005.
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firmed by the injection of fluorescent lectin in the tail vein of the
mice which overlapped with human CD31+ cells (Fig. 4B). Im-
plants with an engineered vasculature (group 3) were more per-
fused as compared to implants without an engineered vasculature
(group 1: 9 lumens∕mm2, group 3: 23 perfused lumens∕mm2, 5
mice, p ¼ 0.014, Fig. 4C). The activation of the engineered vas-
culature using Shh (group 4) further improved implant perfusion,
resulting in a total density of 41 perfused lumens∕mm2 (p ¼ 0.02,
Fig. 4C). This vascular density is typical of highly vascularized
tissues (6). Engineered blood vessels can be unstable, prone to
remodeling and regression in vivo (8). Here, we observed that
(i) cord-like (nonlumenized) structures present in vitro were ab-
sent after implantation (Fig. 4A and Fig. S5) and (ii) the density
of lumens formed in vitro correlated with the density of lumens
perfused in vivo (Fig. 2A and 4C). These results suggest that lu-
minized vessels have a more stable, functional phenotype and
promote higher perfusion then cord-like structures upon implan-
tation. This correlates with recently published observations that
implanted vessels enhance implant perfusion partly via the re-
cruitment of host-derived blood vessels (9). In vascularized im-
plants, perfused blood vessels were derived for 60% þ∕ − 3%
from the mice (hCD31-) and for 40% þ∕ − 3% from the im-
planted huvEC (hCD31+). Part of the capillaries were positive
for the pericyte marker smooth muscle actin (Fig. S6), an obser-
vation consistent with the pericyte heterogeneity of the vascular
bed (28).
Tissue Engineered Implants Recapitulate Intramembranous and Endo-
chondral Ossification. After 5 weeks, a cartilage tissue aligned the
inner part of the implants. This cartilage included round cells in
large lacunae surrounded by proteoglycans (Alcian blue positive,
Fig. 4 D and E). Pericellular collagen type X, an extracellular ma-
trix specific of hypertrophic cartilage (Inset, Fig. 4E), aligned the
newly formed bone osteoids as expected during the process of EO
Fig. 2. Exogenous Shh improves the in
vitro development of the vascular net-
work. Multicellular aggregates treated
with a physiological range of concentra-
tions of Shh (0–30 nM) developed a typi-
cal morphogen response which either
decreased (0.5 nM) or increased (10–
30 nM) the number of vascular lumens
(A). This resulted in a total lumen area
covering up to 5.5% of the tissue area
(10 nM) (B). The Shh-induced formation
of lumens was further inhibited by cyclo-
pamine (C). A later stimulation between
day 9 and 12 was sufficient to increase
the number of lumen (D) and was simi-
larly induced by purmorphamine, a
known pharmacological activator of the
canonical Hh pathway (E). Classical direct
effectors of the angiogenic cascade (TGF,
VEGF, Ang1) did not increase the number
of lumens formed (F). (G–H) The physio-
logical range of concentrations of Shh
affected differently the size-distribution
of lumens [white arrow heads in (G) indi-
cate lumens]. A wider, normal distribu-
tion typical of the vascular tree only
formed at a concentration of 10 nM
(see also Table S1). Aggregates treated
with 0, 0.5, and 30 nM Shh had an expo-
nential distribution with prevalent small
lumens (G, H). n ¼ 4 sections × 4 samples
for each experiment. Errors bars are S.D.
* signifies a p-value <0.05, ** a p-value
<0.005.
Fig. 3. Shh does not regulate the formation of cartilage or bone extracel-
lular matrix. (A) Quantitative RT-PCR for collagen I, collagen type II, aggrecan,
and Collagen X showed that Shh stimulation (10 nM) regulated collagen type
X mRNA (21 fold up, p ¼ 0.04) without affecting collagen type I, collagen
type II and aggrecan mRNA levels. n ¼ 3, errors bars are S.D. The presence
of collagen type I proteins was confirmed (see Fig. S4). (B) Neither the pre-
sence of collagen type II and X proteins was detectable by immunofluores-
cence (top row, collagen type II). The induction of a collagen type II cartilage
ECM using TGFb1 (10 ng∕mL) resulted in the concomitant disappearance of
the CD31+ network (bottom row, see also Fig. 2F). * signifies a p-value <0.05.

















(Fig. 4 D, G, and J). The peripheral part of the implants included
large osteoids of woven bone (green staining, Fig. 4G) including
red, freshly secreted, unmineralized matrix (Fig. 4H). Osteoids
partly aligned the osteoinductive particles and included osteo-
clasts as expected during local IO (27). During EO, the cartilage
matrix is remodeled via a digestion by osteoclasts (bone-resorbing
cells). We observed lines of tartrate-resistant acid phosphatase
(TRACP-) positive osteoclasts at the bone-cartilage interface
(Inset, Fig. 4J). We observed Lamellar bone using polarized light
(Fig. S6). These results demonstrate that implants recapitulated
both IO and EOwith the intermediate production of hypertrophic
cartilage including collagen type X, the digestion and remodeling
of the cartilage by osteoclasts. We speculate that, as previously
demonstrated (1, 4), the newly formed osteoids originate from
the differentiation of implanted hMSC and from mesenchymal
cells from adjacent, injured connective tissue (i.e., muscle).
Contribution of the Engineered Vasculature to the Formation of
Immature Skeletal Tissues in Vivo.We quantified the amount of car-
tilage tissue and bone osteoids formed after 5 weeks of implanta-
tion. The cartilage tissue covered between 5 and 25% of the
implant area (Alcian blue positive, Fig. 4F). Bone osteoids cov-
ered 41% of the implant area in the control group (Group 1),
45% upon treatment with Shh (Group 2, paired Student T-Test,
n ¼ 5, n.s. p ¼ 0.36), 49% in implants including an engineered
vasculature (Group 3, n.s. p ¼ 0.2) and 50% in implants including
a Shh-activated engineered vasculature (Group 4, p ¼ 0.003,
Fig. 4K). Implants without cells did not form any bone. Besides
a significant increase in osteoids formation in group 4 vs. group 1,
the synergetic effect of huVEC and Shh did not improve the for-
mation of immature bone as compared to huvEC or Shh alone
(group 4 vs. group 2 and 3). We concluded that the in vitro devel-
opment of the vasculature did not improve the formation of
immature bone osteoids.
The Implant Matures into a Bone Organ. To test the effect of in vitro
vascular development on the formation of mature bone, we ana-
lyzed implants 8 weeks after implantation. Mature bone formed
which was structurally similar to normal bones with regions of
compact and interconnected trabecular structures (Fig. 5A). Very
little cartilage tissue was found after 8 weeks (Fig. 5B, black arrow
head) which was again aligning the newly formed bone (Fig. 5B,
white arrow head). These observations suggest the completion of
the process of EO. Bone was mineralized, had blood vessels
(Fig. 5C, black arrow) and bone surface lining osteoblasts synthe-
sizing lamellar bone (Fig. 5C, white arrow). Bone lacunae formed
in 4∕6 mice which were phenotypically similar to bone-marrow
cavities (Fig. 5C, black arrow). The formation of bone-marrow
cavities was previously described as related to EO (29). We con-
cluded that the implants recapitulated some aspects of endochon-
dral bone repair leading to the formation of mature bone and
contained elements which might initiate the formation of an ec-
topic bone-marrow cavity.
Contribution of the Engineered Vasculature to the Formation of
Mature Bone Tissue in Vivo. We quantified the amount of mature,
mineralized bone (cross-sections, basic fuchsin staining Fig. 5 E–
H, 5 mice). Implants including a Shh-activated engineered vascu-
Fig. 4. Implants recapitulate endochondral ossification and engineered blood vessels enhance implant perfusion. Implants composed of cellular aggregates
with osteoinductive ceramic particles were placed subcutaneously in mice, explanted, and analyzed after 5 weeks. Cellular aggregates were formed with hMSC
(group 1, control group), hMSC stimulated with 10 nM Shh (group 2), hMSC with huvEC (group 3), or hMSC with huvEC stimulated with 10 nM Shh (group 4)
(A–C) Functional perfusion of the engineered blood vessels. (A) Following implantation, human CD31+ lumens included erythrocytes and (B) were perfused
by fluorescently labeled lectin injected into the mouse tail vein. (C) Shh-activated engineered blood vessels increased implant perfusion from
9 perfused lumens∕mm2 to 41 perfused lumens∕mm2 (Paired Student T -Test, n ¼ 5, p ¼ 0.019). 40–43% of the total perfused blood vessels were human
(dashed area). (D–K) Formation of skeletal tissues. (D) A cartilage tissue formed, including round cells in large lacunae surrounded by proteoglycans (Alcian
blue positive). (E) The cartilage tissue was partly hypertrophic (collagen type X, insert in E) and covered 5–25% of the implant area (F, n.s. between the four
groups, paired Student T -Test, n ¼ 5). (G–H) Bone osteoids formed at the periphery of the osteoinductive particles and at the interface with the cartilage tissue
(Masson-Glodner staining, bone-cartilage interface is shownwith black arrows D, G). (H) Osteoids included red, freshly secreted, nonmineralized matrix (in H: o
is osteoids, n.m. is nonmineralized matrix). (I, J) Cartilage tissue aligned the bone osteoids (haematoxylin-eosin staining (J: c is cartilage, wb is woven bone,
dashed white line delimits cartilage-osteoids interface). Lines of osteoclasts assessed the digestion and remodeling of the cartilage matrix at the bone-cartilage
interface (TRACP staining insert in J). (K) Implants including Shh-activated engineered vasculature formed more bone osteoids as compared to the control
(planar sections of the implants, paired Student T-Test, n ¼ 5, p ¼ 0.003). D, G, I are consecutive sections from the same implant (group 4). Errors bars are S.D. .
Scale bars are 500 μm (D, G, I) and 200 μm (E, H, J).
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lature (group 4) were filled with significantly more bone as com-
pared to the control group (11% of implant area in group 4 vs.
2.6% in group 1, p ¼ 0.02, paired student T-Test, n ¼ 5). Implants
in groups 2 and 3 formed similar amounts of mature bone as com-
pared to the control group (1.3% in group 2 ; 3.1% in group 3). To
confirm these results, we normalized the area of bone to the area
of the ceramic scaffold. The normalized area of bone formed in
group 4 was again significantly higher than in the control group
(17.4% for group 4 vs. 4.6% for group 1, p ¼ 0.02, paired Student
T-Test, n ¼ 5). One mouse which did not form bone in the group 1
(control group) formed bone in group 4 (Shh-activated engi-
neered blood vessels). These results suggest that the in vitro de-
velopment of engineered blood vessels is necessary to contribute
to and enhance the formation of mature bone tissue in vivo. En-
gineered blood vessels in an earlier developmental state fail to
contribute to the formation of new mature bone tissue.
Discussion
Bone is one of the few tissues which have the potential to fully
repair (1). However, the rapid regeneration of large defects is still
very challenging (30). Currently, cell-based therapies exploit the
process of intramembranous ossification, rely on a large amount
of filling biomaterial to stabilize the wound, are limited in size by
delayed vascularization (5, 31), and fail in human clinical appli-
cations (30). Here, we hypothesize that such limitations can be
circumvented by mimicking endochondral bone repair, a stepwise
differentiation of a highly vascularized tissue into cartilage and
bone. In recent evidences, we showed that an engineered vascu-
lature can contribute to the vascularization and survival of an
implant (6, 19). Here, we demonstrate that the developmental
progression of engineered blood vessels (i) is modulated by
the endogenous and exogenous Hh signaling (vascular lumens
number, size, and size distribution), (ii) enhances tissue perfusion
in vivo, and (iii) is necessary to contribute to and enhance the
formation of mature bone tissue in vivo. The regulation of two
Hh canonical inhibitors (GAS1 and RAB23) upon Hh inhibition
along with the effect of the Smo activator Purmorphamine both
argue for a contribution of the canonical pathway to lumen
formation. This effect might result from a direct regulation of en-
dothelial cell morphology through the modulation of actin stress
fibers (32) and from the production of angiogenic molecules in
interstitial cells (11).
This study suggests that the in vitro development of engineered
vasculatures leads to a more functional, stable vasculature in vivo.
The density of lumens formed in vitro correlated with the density
of lumen perfused in vivo. In addition, nonlumenized, cord-
like structures, formed in vitro were absent after explantation.
We speculate that the rapid perfusion of the engineered vessels
by the blood flow induces a selection and maintenance of the
lumenized capillaries while nonperfused cord-like structures pro-
gressively regress.
The regenerating callus is highly vascularized (2). In this study,
solely implants including a Shh-activated vasculature contributed
to and enhanced the formation of mature bone tissue. Besides its
classical role in improving oxygen, nutrients, and ions exchanges,
the vasculature plays an inductive role. Molecules including
VEGF and Hypoxia-inducible factors (HIF1a, HIF2a) directly
contribute to chondrocytes survival (33), chondrocytes hypertro-
phy (34), and osteoblast differentiation (35). Concomitantly, the
vasculature recruits osteoclasts, mesenchymal and hematopoietic
progenitors to the bone-forming sites and seed the hematopoietic
niche (1). We speculate the increased bone formation results
from a combination of improved mass transport (i.e. oxygen,
cells, ions) and vascular inductive function.
We observe the remodeling of a vascularized implant through a
combination of intramembranous and endochondral ossification.
This implant closely mimicks the natural regenerative process of
bone (1). This procedure is clinically relevant, using human adult
stem cells in serum-free condition. The use of alternative sources
of endothelial cells was previously investigated by us (20). In
further investigations, this protocol shall be tested in mechani-
cally challenged orthotopic sites. We hypothesize that the remo-
deling of the implant through a fibrocartilagenous phase might
demonstrate improved compliance to stabilize the fracture, resist
mechanical deformation and solicitations using less biomaterial.
We propose that Shh promotes the in vitro development of an
engineered vasculature whose developmental state determines its
in vivo contribution to the formation of mature bone. Due to
pleiotropic roles of the vasculature in tissue development and tis-
sue function, we believe cell-based therapies will strongly benefit
from engineered vasculatures.
Fig. 5. Solely implants including a Shh-activated engineered vasculature enhance the formation of mature bone tissue. (A–D) Implants (same four groups as in
Fig. 4) were placed subcutaneously in mice, explanted after 8 weeks, and analyzed for the formation of mature bone. (A–D) Planar sections (10 μm-thick, basic
fuchsin staining) revealed the formation of trabecular-like bone structures (A). Small amount of cartilage (B, black arrow) was aligning areas of mature bone
(B, white arrow). The mature bone included bone lining cells (C, white arrow) and blood vessels (C, black arrow). Bone lacunae formed which were filled with a
tissue phenotypically similar to bone marrow (D, black arrow). (E–H) Implant with a Shh-activated vasculature included a larger area of mature bone as com-
pared to implants with hMSC alone, hMSC treated with Shh or hMSC and huvEC (G, 4.2 fold, 7 μm-thick cross-sections of the implants, basic fuchsin staining,
paired Student T -Test, n ¼ 5, p ¼ 0.02 (D). A similar increase in mature bone formation was observed upon normalization to the area covered by ceramic
scaffolds (H, 3.8 fold, paired Student T -Test, n ¼ 5, p ¼ 0.02), Errors bars are S.D.


















Bone marrow aspirates were obtained from donors with written
informed consent. hMSCs were isolated and proliferated as de-
scribed previously (3). Alternatively, hMSC were obtained from
Lonza (Lonza Group Ltd.). Human umbilical vein endothelial
cells (huvECs) were purchased from Lonza (Lonza Group Ltd.).
Coculture of hMSC (92%) and hUVEC (8%) were previously
optimized (19–20) and obtained by resuspending a total of
150,000 cells per spherical aggregate in 2 mL of differentiation
medium and seeded in a well of a Deepwell 96 well-plate (Nunc).
The plate was inverted to form a drop hanging from each well.
Recombinant human Sonic Hedgehog N-terminus (20 kDa) in
0.1% BSA was supplemented to the culture medium at described
physiological concentrations ranging from 0.5 to 30 nM. To eval-
uate the effect of prevascularization and Shh on ectopic bone
formation by hMSCs and huvEC, spherical aggregates
(1;500;000 cells∕implant). were pooled with osteoinductive
biphasic calcium phosphate (BCP) ceramic granules of 100 μm
prepared and sintered at 1,150 °C as described previously (36)
and incorporated in 300 μL of 2 mg∕mL rat tail collagen (BD
Bioscience). Implants were subcutaneously implanted in immune-
deficient mice (Hsd-cpb:NMRI-nu; Harlan) for 5 and 8 weeks. All
experiments were approved by the local Animal Experimental
Committee. The resulting tissues were evaluated through micro-
array, PCR, histology, and immunohistochemistry as described in
the supplementary data. A detailed description of all material and
methods is included in the SI Text.
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